ABSTRACT
Nonachlazine infused in the form of a solution penetrates rapidly the blood and organs. In experiments on cats it was shown that infusion of the drug into the stomach enriches the speed of blood flow and oxyhemoglobin amount in the coronary sinus blood after 2--3 minutes. Heart oxygen consumption increases slightly. Nonachlazine solution is little toxic. As a result of pharmacological research it is recommended for removing angina pectoris attacks in patients irresponsive to nitroglycerin.
Subject(s)
Angina Pectoris/drug therapy , Nonachlazine/therapeutic use , Phenothiazines/therapeutic use , Animals , Cats , Coronary Circulation/drug effects , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Lethal Dose 50 , Male , Mice , Nonachlazine/metabolism , Nonachlazine/toxicity , Rats , Solutions , Time Factors , Tissue DistributionABSTRACT
The results obtained by a study of acute and chronic toxicity of nonachlazine--a new original coronary-active agent endowed with antianginal properties are reported. Nonachlazine has been found to have a sufficiently wide range of therapeutic action. With its repeated (for 36 days) oral introduction to rats in an effective dose of 10 mg/kg the drug does not produce any adverse effect on the general condition of the animals, reduces but insignificantly their weight gain, fails to exert any damaging effect on the blood system, does not change biochemical characteristics featuring the function of the liver, nor evokes any pathohistological changes of the internal organs. Nonachlazine has no locally irritating effect on the gastro-intestinal tract and is a compound producing but a slight stress action.